Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 and up

PET scan to image MMP activity in abdominal aortic aneurysm

Official title: PET Imaging of MMP Activation in AAA: Clinical Component

Run by Washington University School of Medicine · NCT07473102 · Data updated 2026-11-12

We will test whether a new PET tracer ([64Cu]-RYM2) can safely image MMP activity in people with abdominal aortic aneurysm and in healthy volunteers.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment28 (estimated)
SponsorWashington University School of Medicine
Academic / other
Drugs / interventionsradiation
Locations1 site (St Louis, Missouri)
StatusRecruiting
StartedNovember 3, 2025
Main results expectedMarch 31, 2027
Study endsMarch 31, 2027
Registry record updatedMarch 18, 2026
Trial IDNCT07473102 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with a diagnosed abdominal aortic aneurysm who are scheduled for surgical repair, and separate healthy volunteers who meet the imaging inclusion criteria.

Probably not a fit

People who are pregnant or breastfeeding, have severe renal impairment (GFR <30 mL/min/1.73 m2), cannot lie still in a scanner or have claustrophobia, or exceed the BMI limit are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human protocol administers [64Cu]-RYM2 followed by PET/CT to characterize safety, biodistribution, and radiation dosimetry in healthy volunteers. In patients with abdominal aortic aneurysm who undergo surgical repair, preoperative PET imaging will be used to study tracer pharmacodynamics and imaging features will be compared with ex vivo measurements from resected aneurysm tissue. Imaging sessions require participants to lie supine in the PET/CT scanner for about one hour and to follow breathing instructions during the CT portion. The primary goals are to establish safety, dosimetry, and imaging-to-tissue correlation rather than to provide therapeutic benefit.

Why it matters

Potential benefit: If successful, the tracer could enable noninvasive detection of MMP activity in AAAs and help identify aneurysms at higher risk of growth or rupture to better guide timing of intervention.

How similar studies have gone: This is the first human use of [64Cu]-RYM2, while related molecular PET approaches for imaging protease activity have shown promising preclinical results but limited clinical data to date.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria: Healthy Volunteers

* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions.
* Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.
* Capable of lying still and supine within the PET/CT scanner for \~1 hour and follow instructions for breathing protocol during the CT portion.
* No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year.
* No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
* BMI ≤ 40

Exclusion Criteria: Healthy Volunteers

* Inability to receive and sign informed consent;
* Pregnant (confirmed by urine pregnancy test) and/or breastfeeding
* Patient with chronic renal disease whose glomerular filtration rate (GFR) is less than 30 mL/min/1.73 m2
* Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.
* Is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the PET imaging procedures due to chronic back/shoulder pain or arthritis as assessed by physical examination and medical history).
* Currently using recreational drugs.
* Body weight of \>300 lbs. (weight limit of the PET table).
* Currently enrolled in another study using an investigational drug or underwent a study the last year involving investigational use of radiotracers or CT would confound results or with a radiation exposure when combined with this study would be deemed as excessive by the Sponsor-Investigator.

Inclusion Criteria: Patients with AAA electively or semi-electively scheduled for surgical repair

* Men or women 40-80 years of age
* Willing and able to provide informed consent
* Medically managed hypertension and hyperlipidemia
* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions
* Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol
* Patients with AAA indicated for surgical repair (5.0 \[female\] - 5.5cm \[male\]), incidentally identified large(r) AAAs (\>5.5 or 6.0 cm), and rapidly expanding AAAs (\> 0.5 cm in 6 months or \> 1 cm in 12 months) per Guidelines of the Society for Vascular Surgery.

Exclusion Criteria: Patients with AAA electively or semi-electively scheduled for surgical repair

* Inability to receive and sign informed consent.
* Currently enrolled in another study using an investigational drug
* Pregnant (confirmed by urine pregnancy test) and/or breastfeeding
* Patient with chronic renal disease whose GFR is less than 30 mL/min/1.73 m2
* Documented allergy to iodinated contrast and/or shellfish
* Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.
* Inability to tolerate 60 minutes in a supine position with arms down at sides, as necessary for PET/CT.
* Other conditions such as symptomatic/recently treated coronary disease, cancer requiring oncologic management, or autoimmune/inflammatory diseases (e.g., rheumatoid arthritis or multiple sclerosis).
* Non-AAA volunteers may not carry a diagnosis of aortoiliac occlusive disease, as documented by their treating vascular surgeon, as significantly progressed atherosclerotic disease may demonstrate exaggerated, associated MMP activity.

Where it's running

  • Washington University School of Medicine
    St Louis, Missouri, United States
    Recruiting

Study contacts

  • Principal investigator: Robert Gropler, MD — Washington University School of Medicine
  • Study coordinator: Kitty Harrison, RN, BSN
  • Email: kittydharrison@wustl.edu
  • Phone: 314-747-0183

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.